Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer

被引:7
|
作者
Witjes, J. Alfred [1 ]
Feikema, Astrid A. H. [1 ]
机构
[1] Radboudumc, Dept Urol, Nijmegen, Netherlands
来源
CANCER MANAGEMENT AND RESEARCH | 2021年 / 13卷
关键词
bladder cancer; cystectomy; trimodality treatment; oncological outcome; functional outcome; organ preservation; RADICAL CYSTECTOMY; TRANSURETHRAL RESECTION; OUTCOMES; THERAPY; CHEMOTHERAPY; GUIDELINES; SURGERY;
D O I
10.2147/CMAR.S294099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radical cystectomy (RC) is the treatment of choice and is strongly recommended for patients with pT2-4aN0M0 bladder cancer in both the European Association of Urology (EAU) and American Urological Association (AUA) muscle-invasive bladder cancer (MIBC) guidelines. RC is a challenging operation, with significant perioperative and postoperative morbidity and mortality, having short-term complication rates between 14.4% and 21.7%, and long-term oncological survival rates ranging from 60% after 5 years to 43% after 10 years. The impact on quality of life (QoL) in patients after treatment for bladder cancer is significantly worse than in other pelvic cancers. Although RC is strongly recommended as the gold standard, there is a need for bladder-sparing options in MIBC. Attempts to improve mortality and morbidity rates after RC have been made by implementing Enhanced Recovery After Surgery (ERAS), robot-assisted RC, and sexual function-preserving techniques. None of these significantly improves QoL or functional outcome. Because of the invasiveness of RC, other therapeutic options have been evaluated. Transurethral resection of the bladder tumor (TURB) plays an important role in the diagnostic evaluation of MIBC and has also been reviewed as a curative option, although the oncological results appear inferior to RC. Furthermore, improved radiotherapy (RT) and widely used chemotherapy, both as mono therapeutic options in bladder cancer, are not as effective as radical surgery, with lower survival rates. Trimodality treatment (TMT) in bladder cancer combines TURB with chemotherapy and RT. The goal of TMT is preserving the bladder and QoL without compromising oncological outcome. A 2018 review showed no difference in overall survival rates between RC and TMT (30.9% vs 35.1%), with lower survival rates after RC than TMT in the first year of follow-up, probably due to higher postoperative mortality. For a selected group of patients, TMT is to be recommended, and it is the most favorable option out of the organ sparing strategies in MIBC.
引用
收藏
页码:7833 / 7839
页数:7
相关论文
共 50 条
  • [21] Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review
    Ploussard, Guillaume
    Daneshmand, Siamak
    Efstathiou, Jason A.
    Herr, Harry W.
    James, Nicholas D.
    Roedel, Claus M.
    Shariat, Shahrokh F.
    Shipley, William U.
    Sternberg, Cora N.
    Thalmann, George N.
    Kassouf, Wassim
    EUROPEAN UROLOGY, 2014, 66 (01) : 120 - 137
  • [22] Chemotherapy for Muscle-Invasive Bladder Cancer
    Trenta, Patrizia
    Calabro, Fabio
    Cerbone, Linda
    Sternberg, Cora N.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (01) : 1 - 14
  • [23] Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer
    McHaffie, Derek R.
    Kruser, Tim J.
    Gaston, Kris
    Mahoney, John
    Graham, David
    Haake, Michael
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (06) : 271 - 278
  • [24] Therapeutic interventions targeting organ preservation in muscle-invasive bladder cancer: a review
    Georgios Koukourakis
    Vassilios Kouloulias
    Georgios Zacharias
    Anastasia Sotiropoulou-Lontou
    Michael Koukourakis
    Clinical and Translational Oncology, 2011, 13 : 315 - 321
  • [25] Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
    Tholomier, Come
    Souhami, Luis
    Kassouf, Wassim
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (06) : 2920 - 2937
  • [26] Organ preservation in muscle-invasive urothelial bladder cancer
    Niglio, Scot A.
    Purswani, Juhi M.
    Schiff, Peter B.
    Lischalk, Jonathan W.
    Huang, William C.
    Murray, Katie S.
    Apolo, Andrea B.
    CURRENT OPINION IN ONCOLOGY, 2024, 36 (03) : 155 - 163
  • [27] Elective Bladder-Sparing Treatment for Muscle Invasive Bladder Cancer
    Lendinez-Cano, G.
    Rico-Lopez, J.
    Moreno, S.
    Fernandez Parra, E.
    Gonzalez-Almeida, C.
    Camacho Martinez, E.
    ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (01): : 7 - 13
  • [28] Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
    Omar M. S. El-Taji
    Sameer Alam
    Syed A. Hussain
    Current Treatment Options in Oncology, 2016, 17
  • [29] Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
    Peyrottes, Arthur
    Ouzaid, Idir
    Califano, Gianluigi
    Hermieu, Jean-Francois
    Xylinas, Evanguelos
    MEDICINA-LITHUANIA, 2021, 57 (08):
  • [30] Perioperative Chemotherapy for Muscle-Invasive Bladder Cancer
    Booth, Christopher M.
    Siemens, D. Robert
    Li, Gavin
    Peng, Yingwei
    Tannock, Ian F.
    Kong, Weidong
    Berman, David M.
    Mackillop, William J.
    CANCER, 2014, 120 (11) : 1630 - 1638